We present a generic and versatile method for functionalization of disulfide-stabilized PMA hydrogel capsules (HCs) with macromolecules, including a number of specific antibodies to cancer cells.
For more than a decade, multilayered polymer capsules have attracted interest as versatile candidates for a diverse range of biomedical applications, including drug delivery vehicles, 1-3 microreactors, 4 and as hierarchical components of artificial cells. 5, 6 Significant effort has focused on engineering multilayered, responsive and functional capsules with control over their physicochemical properties, such as size, permeability, and stability. Recently, we developed a redox-responsive multilayered hydrogel capsule system based on thiolated poly(methacrylic acid) (PMA SH ). 7 An approach to stabilize such capsules is based on reversible disulfide linkages, as these bonds are stable in extracellular milieu, but then can degrade in simulated intracellular conditions. 8 These PMA hydrogel capsules (HCs) are prepared by the sequential adsorption of PMA SH and poly(N-vinyl pyrrolidone) (PVPON) on silica particles, mediated through hydrogen bonding. Following assembly, the PMA SH multilayers are stabilized by oxidation of the thiol groups to form disulfide bonds. The silica templates are then dissolved and the PVPON is released from the multilayers, resulting in PMA HCs. Several studies have shown that this assembly procedure has the potential to controllably tailor key properties of the PMA HCs, including size, permeability, 9 cargo loading, 10 and triggered release. 11 Various therapeutics, including nucleic acids, 12 peptide vaccines, 10 and hydrophobic chemotherapeutic drugs, 13, 14 have been encapsulated in these capsules and effectively delivered to human cells in vitro and in vivo. 15, 16 More recently, subcompartmentalized PMA HCs containing intact liposomes 17, 18 or smaller PMA HCs 19 have been reported, suggesting the potential of PMA HCs for microencapsulated catalysis and advanced drug delivery. 20 Given the complexity of biological environments, it is often desirable to functionalize capsules with biomolecular binding partners to achieve specific interactions. 21 For example, cells can be specifically targeted by functionalizing the surface of capsules with appropriate antibodies, or specific cell signaling pathways can be activated by conjugating capsules with activating ligands. In cancer drug delivery, the specific and targeted delivery of a drug is a crucial goal in the development of drug delivery carriers, as it can potentially reduce the drug toxicity to healthy tissues, while delivering a high dosage to the targeted cancer cells. 22, 23 A number of covalent coupling chemistries, including click and thiol/maleimide reactions, have been used to covalently conjugate biomolecules to a range of surfaces. 24 For instance, we recently reported the functionalization of PVPON-click capsules with specific antibodies and in vitro targeting to cancer cells. 25 Additionally, functionalization of multilayered capsules with specific antibodies can also be achieved through electrostatic interactions. 26 The strong non-covalent interaction between biotin and avidin (K d ~ 10 -15 M), which forms a stable complex over a wide pH, ionic strength, and temperature range, 27 represents a versatile strategy to tether biomolecules. In addition, the routine biotinylation of a variety of macromolecules, as has been demonstrated for proteins, 28 peptides, 29 and polymers, 30 enables such materials to interact and/or be immobilized through biotin-avidin interactions, providing a facile coupling and functionalization strategy for developing functional biomaterials.
Herein, we report a generic approach based on biotin/avidin interactions to functionalize PMA HCs with antibodies and illustrate their potential by targeting human colorectal cancer cells in vitro (Scheme 1). Firstly, we synthesized poly(N-vinyl pyrrolidone) (PVPON) via reversible addition fragmentation chain transfer (RAFT) polymerization using O-ethyl S-(phthalimidylmethyl) xanthate as a RAFT agent to introduce a thiol group at one end of the molecule and an amine group at the other (Scheme 2). This heterotelechelic polymer can also be used for various bioconjugation methods, which utilize amine-and thiol-reactive residues. Next, the PVPON with heterotelechelic end groups was conjugated to the outermost layer of PMA HCs through the thiol groups, and reacted with biotin via the amine groups, to generate PMA/PVPON biotin HCs. Furthermore, RAFT polymerization made it possible to controllably synthesize PVPON of various molecular weights, resulting in linkers of different lengths for biofunctionalization of the HCs. The advantage of using PVPON as a linker is that the amount immobilized can be easily controlled by the molecular weight of PVPON, and therefore the number of chains attached to the surface. Additionally, the immobilization of modified PVPON occurs via multilayer assembly, leading to PMA/PVPON biotin , HCs, which can be biofunctionalized. To 5 demonstrate the general applicability of this functionalization protocol, two monoclonal antibodies, humanized A33 monoclonal antibody (huA33 mAb) 31 and epidermal growth factor receptor monoclonal antibody (EGFR mAb) 32 were biotinylated, complexed with NeutrAvidin and individually coupled to PMA/PVPON biotin HCs. Using human colorectal cancer cells (LIM1899), which endogenously express both A33 antigen and EGFR on the cell surface, 33 we demonstrate significantly enhanced cellular binding and internalization of these antibody(Ab)-functionalized capsules compared with control human immunoglobulin (IgG)-functionalized capsules, suggesting that these capsules can specifically interact with cells through antibody/antigen recognition. We anticipate that the versatility of the functionalization approach reported in this study will help realize a range of biofunctionalized carriers with potential for targeted therapeutic delivery.
RESULTS AND DISCUSSION
RAFT Polymerization of PVPON. The ability to control both the molecular weight distribution of polymers and their functional end groups makes RAFT polymerization advantageous for bioconjugation. Specifically, the presence of thiocarbonylthio functionality in RAFT-derived polymers enables bioconjugation through the relevant thiol. 34 PVPON was synthesized in the presence of the Oethyl S-(phthalimidylmethyl) xanthate RAFT agent using azobisisobutyronitrile (AIBN) as the initiator.
The xanthate RAFT agent used in this study has been shown previously to provide good control over "less activated" monomers (LAMs; e.g., vinyl acetate, 1-vinyl-2-pyrrolidinone). 35 In addition, this RAFT agent has the capacity to generate a protected amine end group that can be modified subsequently to give bioreactive end functionality. [35] [36] [37] Following polymerization the molecular weights observed from NMR and GPC were close to the theoretical molecular weights (7, 15 and 30 kDa) and the polydispersities were narrow (below 1.20, Table 1 ). These values are in good agreement with those reported for RAFT polymerization of 1-vinyl-2-pyrrolidinone. 35, 38, 39 It is desirable that polymerization is not brought to full conversion to avoid thiocarbonylthio end group loss via radical-radical polymer 6 coupling and other radical side reactions. 40 Thus, the monomer conversion of the prepared polymers was kept below 85% (final column, Table 1 ).
RAFT PVPON Modification.
Hydrazine has a bifunctional role in the aminolysis of RAFT-derived polymers. 41 As a strong nucleophile, it can drive not only hydrozinolysis of the phthalimidomethyl group of the RAFT PVPON polymer with the desired α-amino functionality, but can also give an exposed thiol functionality by cleaving the thiocarbonylthio end group. The deprotection step was performed by treating the RAFT PVPON polymer with hydrazine hydrate in methanol. The conversion of the phthalimidomethyl group to α-amine was confirmed by 1 H NMR spectroscopy ( Figure S1a ), in which the terminal phthalimidomethyl group has a characteristic 1 H NMR chemical shift as two broad "doublets" at δ 7.71 and 7.83 ppm. The 1 H NMR spectra clearly indicate the disappearance of the phthalimide end group, reflecting the successful conversion to α-amine ( Figure S1b ). The amine end group could not be detected by 1 H NMR, as its chemical shift appears between δ 0.5 -4.5 ppm as a broad signal, which would be overlapped by polymer backbone signals.
Although the use of hydrazine hydrate can transform the thiocarbonylthio end group to a thiol functionality (whilst deprotecting the amine), the two-step approach was used to ensure the presence of a thiol end group on the PVPON polymers (Scheme 2). To obtain polymer chains with a thiol end group, the thiocarbonylthio moiety on the RAFT PVPON chain was cleaved with sodium borohydride.
The resulting thiol was immediately reacted with Ellman's reagent to form a mixed disulfide with a characteristic absorbance at 335 nm. The terminal thiocarbonylthio group on the RAFT-synthesized PVPON has a characteristic absorbance maximum at 305 nm, and the disappearance of the peak at 305 nm and the appearance of a peak at 335 nm confirm the successful reaction ( Figure S2 ). Further evidence of the reaction between the polymer and the 2-nitro-5-thiobenzoate (NTB) moiety of Ellman's reagent was obtained by 1 H NMR spectroscopy, which revealed the appearance of additional signals at chemical shifts of 7.54 and 7.77 ppm ( Figure S1c ). The conjugation of the thiol to the NTB moiety protects the terminal thiol from side reactions and, more importantly, is primed for thiol-disulfide 7 exchange.
To allow selective bioconjugation, the modified PVPON with α-amine and protected ω-thiol can be reacted with a small molecule that facilitates covalent linkage to an amine, such as Nhydroxysuccinimidyl (NHS) ester-activated biotin. Biotin binds with high affinity to avidin and its derivatives, such as streptavidin or NeutrAvidin. 27 N-hydroxysuccinimidyl ester-activated biotins (NHSbiotin) are most commonly used because NHS esters react efficiently with primary amino groups at pH 7 -9 to form stable amide bonds. 42 PVPON with an α-amino end group was reacted with biotin-Nhydroxysuccinimidyl ester (biotin-NHS) at pH 7.5 for at least 2 h. Biotin incorporation was confirmed using the EZ-Link ® Sulfo-NHS-LC-Biotinylation Kit. For the given samples a ratio of 0.9 to 1 was obtained. This result provides additional evidence for the phthalimide conversion into a primary amine, and shows retention of amine reactivity.
PMA/PVPON HC Formation. To obtain hollow capsules we used the layer-by-layer (LbL)
approach, which comprises the sequential deposition of polymers onto sacrificial particles. In previous studies, we have shown that the polymer pair PVPON and PMA SH can be adsorbed onto particles without compromising their colloidal stability, a feature essential for reliable capsule assembly. 19 Oxidative crosslinking of PMA SH and removal of the core particles generate stable PMA hydrogel capsules (HCs). In this study, RAFT-derived PVPON was modified to possess a single terminal thiol group, through which the PVPON was attached to generate PMA/PVPON HCs following the removal of the particle templates. The multilayer assembly was monitored using flow cytometry analysis of PVPON modified with an Alexa Fluor 488 (AF488) fluorescent label coupled through the α-amino group. The sequential deposition of the PMA SH and AF488-PVPON resulted in a linear increase in capsule fluorescence ( Figure S3 ). We have previously shown the release of PVPON layers from intact capsules following a pH change from acidic pH (pH 4) to physiological pH (pH 7.2) due to disruption of hydrogen bonding between the polymer pairs. 7 However, with the current capsules, flow cytometry reveals that around 72% of the PVPON was retained within the capsules on increasing the pH to 7. Our previous studies on PMA HC formation suggested that the optimal thiol percentage to obtain stable and well crosslinked capsules was between 9 and 12%. 43, 44 Similar results were observed in this study for PVPON integration ( Figure S4 ). PMA thiolation of less than 9% provides a lower number of thiols for efficient crosslinking between the thiol groups of PVPON and PMA HCs. Thiolation of more than 20% produces a more hydrophobic PMA with a more coiled polymer structure, which we postulate leads to more intramolecular crosslinking and, consequently, less thiol groups available for intermolecular interactions, 43 such as the formation of disulfide bonds between modified PVPON and PMA SH .
It is possible to calculate the number of chains on the surface of the capsules by using the surface coverage of PVPON (1.4 mg m -2 ), 11 and assuming that the efficiency of the reaction between α-amine and NHS-ester approaches 100% (see Supporting Information). The highest percentage of polymer retained, and consequently the highest number of chains on the surface of the capsules, was observed with low molecular weight PVPON (7 kDa) ( Figure 2a ). Each individual polymer chain possesses a single thiol end-functionality. We would expect that more chains of lower molecular weight polymer can be adsorbed onto a given surface area compared to larger chains, resulting in an increased number of thiol groups available for incorporation into the PMA SH network. As the molecular weight of PVPON increased, the percentage of PVPON retained and the number of chains decreased, suggesting a dilution of the thiol content on the surface (higher ratio between the thiol end group and the main chain) ( Figure   2a ).
The use of various crosslinkers to stabilize PMA HCs also modulates the degree of PVPON retention on the surface of the capsules (Figure 2b) . In previous studies we have described the formation of disulfide-stabilized PMA capsules using the oxidizing agent Chloramine T (CaT) or by thiol-disulfide exchange with a thiol-activated polymer. 45 More recently, we have extended the crosslinking approach by implementing homobifunctional crosslinking reagents containing the thiol-reactive moiety, maleimide. 19 The use of the oxidizing agent (CaT) alone showed only around 70% efficiency of PVPON incorporation, suggesting incomplete conversion of thiols into disulfide linkages. Crosslinking using reagents with thiol-reactive groups (i.e. maleimides), demonstrated a different behavior. In this study we used two homobifunctional crosslinkers, namely BM(PEG) 2 and DTME, which contain non-cleavable short poly(ethylene glycol) and a redox-cleavable disulfide bridge, respectively. Figure 2b shows that the most efficient crosslinker was BM(PEG) 2 . This is most likely due to the more hydrophilic nature of BM(PEG) 2 in aqueous solution compared to DTME (which is mostly insoluble in aqueous solution), allowing better penetration into the layers. Dithiodipyridine (DTDP) is another crosslinking reagent that is accessible for thiol-disulfide exchange. It has intermediate hydrophobicity, and not surprisingly, it has a corresponding intermediate effect on PVPON retention ( Figure 2b ). We have recently shown promising results for the crosslinking of PMA HCs with DTDP for improved cargo retention. 9 It was determined that the rate of reaction between DTDP-activated thiol and the neighboring thiol on the PMA chain is sufficiently fast to establish a disulfide bridge between the polymer chains. Since there is only a single thiol at the terminus of the modified PVPON, it is clear that not all PVPON can be retained onto the surface of the capsules.
Biofunctionalization of PMA HCs. We next investigated the potential of generating two biorelevant end groups for biofunctionalization of the capsule surface by incorporating biotin into PVPON (PVPON biotin ). We chose to conjugate this small biomolecule (also known as vitamin H) because of the highly specific interaction and high affinity with avidin, 27 and its derivates, such as NeutrAvidin (NAv).
The use of biotinylated antibodies and their specific interaction with avidin for tumor targeting is reported elsewhere. 46, 47 PMA HCs were assembled with PVPON biotin on the surface of the capsules, followed by incubation with FITC-fluorescently labeled NeutrAvidin (NAv-FITC). The effect of the molecular weight of PVPON biotin on the interaction between the biotinylated capsules and the fluorescent protein was monitored by flow cytometry and fluorescence microscopy (Figure 3a) . Flow cytometry analysis of the capsules showed decreasing fluorescence with increased molecular weight of the polymer on the surface. This suggests that the presence of higher molecular weight modified PVPON on the surface results in a smaller number of functional end groups for interaction with the NAv-FITC. The control capsules that lack biotin showed minimal fluorescence arising from NAv-FITC ( Figure 3b (D, E) ), suggesting negligible non-specific interactions between the NAv and the surface of the capsules.
Monoclonal antibodies that can selectively target cancer cells have been exploited for effective cancer therapies. 48 Studies have shown that nanoengineered drug carriers enhance efficacy by increasing the effective concentration of the payload compared to free drug. 13 Therefore, biofunctionalization of drug carriers with monoclonal antibodies (mAb) is expected to further improve the therapeutic index by specific targeted delivery. We previously reported on the incorporation of antibodies on the surface of PMA-coated silica particles through electrostatic interaction, 26 but this approach is only feasible when charged molecules are present on the surface. To overcome this limitation, herein we developed a versatile method to functionalize PMA HCs with monoclonal antibodies via the strong interaction between NeutrAvidin and biotin. The PMA/PVPON biotin HCs were incubated with the NeutrAvidin/biotin-IgG complex (ratio 1:2). To verify the coupling with IgG, the capsules were further incubated with secondary (Fab specific) fluorescent IgG-FITC antibodies. To distinguish the capsules from the FITC-labeled protein, PMA/PVPON biotin HCs were AF633-fluorescently (red) labeled using the remaining thiol groups on the capsules and AF633 maleimide dye. As shown in Figure 4a , the AF633-labeled PMA/PVPON biotin HCs exhibited strong green fluorescence arising from IgG-FITC. In contrast, the AF633-labeled PMA/PVPON HCs (without biotin) showed negligible levels of green fluorescence. From the known number of PVPON chains on the surface, and assuming that each PVPON chain incorporates one complex, the number of attached antibodies is calculated to be as between (2-20)×10 4 Ab per capsule, depending on the linker length (Table S1 ). To demonstrate the targeting effects using the antibody-functionalized PMA/PVPON biotin HCs, two monoclonal antibodies (mAb), humanized A33 mAb (huA33 mAb) and the anti-epidermal growth factor receptor mAb (EGFR mAb), were used individually to functionalize the AF633-labeled PMA/PVPON biotin HCs. A human colorectal cancer cell line, LIM1899, 49 was chosen for incubation with the Ab-functionalized capsules, as these cells endogenously express both A33 and EGF receptors on the cell surface. Firstly, to evaluate the cell surface binding, Ab-functionalized capsules were incubated with LIM1899 cells at 4 °C for 1 h with a capsule-to-cell ratio of 100:1. Incubation at this temperature (4 °C) prevents cellular internalization by endocytosis. Following this treatment, the unbound capsules were removed, the cells were washed with PBS twice and then analyzed by flow cytometry. In the case of huA33-functionalized capsules, three different lengths of PVPON biotin were tested as a linker to functionalize the capsules as chain length can be crucial for efficient interaction between antigen and antibody. After the incubation, over 90% of cells were associated with capsules for all three types of huA33 mAb-functionalized PMA/PVPON biotin HCs, and in contrast significantly less cellular association was demonstrated for the corresponding IgG-functionalized PMA/PVPON biotin HCs (Figure 5a ). It is also worth noting that the highest mean fluorescence intensity of the cells was shown when the 17 kDa PVPON biotin was used, suggesting that the length of the linker plays an important role in the maximal binding between A33 antigen and huA33 mAb on the surface of the capsules ( Figure S5 ). To demonstrate the general applicability of this approach, anti-EGFR mAb was used to functionalize the PMA/PVPON biotin HCs.
Firstly, the capsules were functionalized with the antibody with linkers of different length. The cells were then incubated with the functionalized capsules at 4 °C for 1 h with a capsule-to-cell ratio of 100:1, followed by analysis using flow cytometry. Consistent with huA33 mAb-functionalized capsules, all three types of EGFR mAb-functionalized capsules showed enhanced binding on the cell surface compared to IgG-functionalized capsules (Figure 5b) . Similarly, the percentage of cells associated with EFGR mAb-functionalized capsules was dependent on the length of the linker used, since the cellular binding with the capsules decreased as the length of the linker increased (Figure 5b ). Furthermore, it is worth noting that the highest percentage of cells associated with huA33 mAb-functionalized capsules was about 90%, whereas the highest percentage of cells associated with EGFR mAb-functionalized capsules was about 50%, suggesting that the targeting effect is also strongly dependent on the specific antibody.
Following the specific binding of the antibody-functionalized capsules with the cell membrane, we sought to investigate the cellular uptake of these functionalized capsules. Based on the binding results, we chose to use 7kDa PVPON biotin to couple with antibodies as it was most effective in targeting cells.
Firstly, the LIM1899 cells were stained with CellTracker green CMFDA to outline the entire cell. The AF633-labeled Ab-functionalized PMA/PVPON biotin HCs (huA33 mAb-, EGFR mAb-and IgGfunctionalized capsules) were then incubated with the cells at 37 °C for 1 h to allow for internalization to occur. After treatment, the cells were washed with PBS to remove excessive capsules and analyzed by confocal microscopy. Both huA33 mAb-functionalized and EGFR mAb-functionalized capsules showed stronger cellular association (including cell surface binding and cell uptake) compared with IgG-functionalized capsules (Figure 5c-e ), in good agreement with cellular binding results obtained by flow cytometry. It was also notable that whereas huA33 mAb-functionalized capsules were strongly associated with the cell membrane, the EGFR mAb-functionalized capsules appeared to be inside the cells, as evidenced by co-localization of the red and green fluorescent signals. This suggests that the kinetics of internalization are different when the capsules are functionalized with two different antibodies. It has been reported that huA33 antigen may be associated with cell adhesion complexes, such as tight junctions, and huA33 mAb exhibits prolonged membrane retention. 50 In contrast, a study has shown that upon binding of ligand to the EGFR on the surface of the cells, the complex aggregates into clusters and is rapidly internalized. 51 Consistent with these findings, PMA/PVPON biotin HCs with huA33 mAb appear to stay predominantly on the cell surface, and only small portions are further internalized. In comparison, EGFR mAb-functionalized capsules are internalized by the cells to a larger extent. Taken together, our results have shown that the functionalization of capsules with monoclonal antibodies lead to specific interactions of capsules with cells via antibody-antigen recognition. The interactions between Ab-functionalized capsules and cells are a complex phenomenon that depends on several variables, including the expression level of antigen on the cell surface, the coverage of antibodies on the capsule surface, the accessibility of antigens and antibodies, as well as cell-intrinsic properties. Future studies will be aimed at obtaining detailed knowledge of each variable to achieve optimized targeting effects for specific antibodies. PVPON Synthesis and Modification. The phthalimidomethyl xanthate RAFT agent and the corresponding RAFT-synthesized PVPON were obtained as previously described. 35 The polymers were analyzed using 1 H NMR and GPC, the results of which are shown in Table 1 .
The terminal phthalimide group of the RAFT synthesized PVPON was converted into a terminal primary amine group by hydrozinolysis. 250 μL of hydrazine hydrate (BDH) was added to a 100 g⋅L -1 solution of RAFT-derived PVPON in methanol and the resulting mixture was stirred at 60 °C overnight.
The excess hydrazine hydrate was neutralized by careful addition of 37% HCl to adjust it to neutral pH.
The NH2 PVPON was isolated by precipitation into acetone, filtered and dried under vacuum overnight.
To ensure full transformation of the thiocarbonylthio end group to a thiol, the RAFT-derived polymer or PVPON after hydrozinolysis was dissolved in 1 M NaBH 4 (Sigma-Aldrich) solution in water, and the reaction mixture was incubated at room temperature (25 ºC) for 2 h. The excess sodium borohydride was neutralized by careful addition of 37% HCl, and was adjusted to pH 7.5 by careful addition of 1 M HCl and NaOH solutions while buffered by the addition of phosphate buffer (0.1 M). To this mixture, an excess of 0.5 M Ellman's reagent (ER, Sigma-Aldrich) in 0.1 M phosphate buffer at pH 7.5 was added, and the reaction was allowed to proceed for 1 h. The resulting polymer ( NH2 PVPON ER ) was isolated using a NAP-25 column (GE Healthcare) and recovered by freeze-drying. The introduction of the 2-nitro-5-thiobenzoate (NTB) moiety is for the purposes of a prolonged storage of the polymer and its characterization.
Fluorescent labeling of NH2 PVPON ER was carried out by incubating 10 mg of polymer in phosphate buffer saline (0.1 M Na 2 HPO 4 , 0.15 NaCl, pH 7.2) with 10 μg of 1 g L -1 Alexa Fluor 488 carboxylic acid, succinimidyl ester dye (AF488NHS, Invitrogen) in DMSO. The reaction between the primary amine end group and N-succinimidyl ester on the fluorescent dye was allowed to proceed for 2 h, after which the polymer was purified using a NAP-5 column (GE Healthcare) and recovered by freezedrying.
Biotinylation of the polymer was carried out by incubating 10 mg of the NH2 PVPON ER in 1 mL phosphate buffer saline (0.1 M Na 2 HPO 4 , 0.15 NaCl, pH 7.2) with a 20-fold molar excess of 0.1 mM Sulfo-NHS-LC-Biotin (Pierce). The reaction between the primary amine on the polymer end group and NHS on the biotin was allowed to proceed for 2 h, after which the polymer was purified via column chromatography using a NAP-5 column (GE Healthcare) and recovered by freeze-drying. Biotin incorporation in the polymer was confirmed using a EZ-Link ® Sulfo-NHS-LC-Biotinylation Kit Multilayer Assembly on Particles. The assembly of PMA HC was performed using a 5 wt% particle suspension (MicroParticles, GmbH) in a similar way to that reported previously. 11 For multilayer assembly, PMA with a thiolation degree of 12% 43 and PVPON (commercially available (Sigma-Aldrich) or RAFT-synthesized PVPON (RAFT-PVPON)) were used.
Biotinylation of Antibodies. Biotinylation of antibodies was carried out according to the procedure provided with the EZ-Link  Sulfo-NHS-Biotinylation Kit (Pierce). This procedure was applied to every type of antibody used in this work. In particular, the aliquot of immunoglobulin (IgG, Sigma-Aldrich) antibody in PBS was mixed with 5× molar excess of 10 mM Sulfo-NHS-Biotin (Pierce) in water to obtain no more than 2 biotin groups per antibody molecule. The mixture was kept under constant mixing at 4 ºC overnight. The next day, the biotinylated antibodies were recovered using Zeba Desalt Spin Columns (Thermo Scientific), according to the manufacturer's instructions. Estimation of biotin incorporation into the antibody was determined according to the procedure provided with the EZ-Link  Sulfo-NHS-Biotinylation Kit in the same way as described above for the polymer.
Functionalization of the Capsule Surface. SiO 2 particles were assembled with multilayers as described above, except for the last layer for which biotinylated PVPON was deposited. The rest of the hollow capsule formation process was followed as reported previously. 11 Following capsule formation, capsules redispersed in 50 µL of MES buffer (50 mM, pH 6) were fluorescently labeled by mixing them with 5 µL of 1 g L -1 Alexa Fluor® 633 maleimide in DMSO followed by overnight storage.
Fluorescently labeled capsules were isolated from the free dye by rinsing three times with MES buffer (50 mM, pH 6). The capsules were then functionalized using the biotin-NeutrAvidin (NAv, Pierce) interaction. In particular, 20 µL of the sample was diluted 10 times with PBS and incubated with a large excess of premixed NeutrAvidin/antibody complex to prevent capsule aggregation for 1 h at 4 °C. The complex was prepared by rapidly mixing 2 parts of antibody (0.1 g L -1 ) with 1 part of NAv (0.1 g L -1 ).
Excess NAv/antibody was removed through centrifugation/redispersion (4 cycles of 3500 g, 5 min).
Taking into account the known number of PVPON chains on the surface, and assuming that each PVPON chain incorporates one complex, the number of antibodies can be calculated for each sample (Table S1 ). However, the final number of antibodies will exceed that calculated since all samples were mixed with an excess of biotinylated antibodies to prevent capsule aggregation. To estimate quantitatively the number of antibody molecules immobilized on the surface of the capsules was not possible due to a large excess of antibody used.
Cell Culture. The human colorectal cancer-derived cell line LIM1899 49 was maintained in RPMI media (Gibco) containing 10% fetal bovine serum (FBS), and ADDS (10.8 μg mL -1 α-thioglycerol, 0.025 U mL insulin, 1 μg mL -1 hydrocortisone) at 37 °C in a 5% CO 2 humidified atmosphere and subcultured prior to confluence using trypsin/EDTA. 
